Chemotherapy and New Drugs in Prostate Cancer

*Nicolas Mottet

Department of Urology, University Hospital, Hôpital Nord, St Etienne, France
*Correspondence to

Disclosure: N.M. has received grants or research support from Takeda/Millenium, Astellas, Pierre Fabre, Sanofi, and Pasteur; and honoraria or consultation fees from Takeda/Millenium, Jansen, Astellas, BMS, Bayer, IPSEN, Ferring, Novartis, Nuclétron, Pierre Fabre, Sanofi, and AstraZeneca.
Received: 17.12.14 Accepted: 13.02.15
Citation: EMJ Urol. 2015;3[2]:103-110.

Download (PDF, 119KB)

Comments are closed.